Allergan Plc (AGN) 314.95 $AGN
KYTHERA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of KYTHERA Biopharmaceuticals, Inc. (KYTH) Over the Proposed Sale of the Company to Allergan plc.
Business Wire - Thu Jul 23, 9:55AM CDT
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of KYTHERA Biopharmaceuticals, Inc. ("Kythera" or the "Company"
(NasdaqGS:KYTH) for potential breaches of fiduciary duties in connection with the sale of the Company to Allergan plc. for approximately $2.1 billion. The Company's stockholders will only receive approximately $75 per share for each share of Kythera common stock they own.
AGN: 314.95 (-0.40), KYTH: 74.37 (-0.07)
Zacks Industry Outlook Highlights: AbbVie, Allergan, Pfizer, Juno and Johnson & Johnson - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 8:30AM CDT
Zacks Industry Outlook Highlights: AbbVie, Allergan, Pfizer, Juno and Johnson & Johnson
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), JUNO: 51.65 (-0.12), ABBV: 70.52 (-0.04)
Inotek Pharmaceuticals elects Dr Richard N. Spivey to board
M2 - Wed Jul 22, 4:58AM CDT
Biopharmaceutical company Inotek Pharmaceuticals (NasdaqGM:ITEK) revealed on Tuesday that it has appointed Richard N. Spivey, PharmD, PhD, to its board of directors.
AGN: 314.95 (-0.40), ITEK: 15.37 (+10.14)
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), ACHN: 8.97 (-0.12), PFE: 34.78 (-0.10), ABBV: 70.52 (-0.04), JUNO: 51.65 (-0.12), LLY: 86.76 (+0.38), SNY: 53.37 (+0.28)
Pharma Stock Outlook - July 2015 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Industry Outlook
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), ACHN: 8.97 (-0.12), PFE: 34.78 (-0.10), ABBV: 70.52 (-0.04), JUNO: 51.65 (-0.12), LLY: 86.76 (+0.38), SNY: 53.37 (+0.28)
Acne Vulgaris Pipeline Review 2015 - 40 Companies & 53 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtb2tv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advancell - Allergan, Inc. - AndroScience Corporation - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Cutanea Life Sciences - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - Dermira Inc. - ELORAC, Inc. - Ensoltek Co., Ltd. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Kasiak Research Pvt. Ltd. - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Nabriva Therapeutics AG - Novabiotics Ltd - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Provectus Biopharmaceuticals, Inc. - QLT Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mt...e_vulgaris
QLTI: 4.01 (unch), FOMX: 10.95 (-0.34), GSK: 42.00 (-0.30), PRTK: 25.84 (-0.57), AGN: 314.95 (-0.40), PVCT: 0.54 (+0.04), DERM: 24.19 (-0.72)
Technical Roundup on Drugs - Generic Equities -- Allergan, Akorn, Ironwood Pharma, Pacira Pharma, and Catalent
PR Newswire - Tue Jul 21, 8:15AM CDT
Equity Research Institute has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Catalent Inc. (NYSE: CTLT). Free research report on Allergan can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AGN On Monday, July 20, 2015, the NASDAQ Composite ended at 5,218.86, up 0.17%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 18,100.41, and the S&P 500 closed at 2,128.28, up 0.08%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
AGN: 314.95 (-0.40), IRWD: 11.41 (+0.07), AKRX: 46.01 (+0.32), CTLT: 30.40 (+0.47), PCRX: 62.10 (-0.03)
Inotek Pharmaceuticals Appoints Richard N. Spivey PharmD, Ph.D. to Board of Directors
Business Wire - Tue Jul 21, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for ocular diseases, today announced that Richard N. Spivey, PharmD, PhD, has been appointed to its Board of Directors.
AGN: 314.95 (-0.40), ITEK: 15.37 (+10.14)
Allergan Launches Bold Campaign For Millennial Women
PR Newswire - Tue Jul 21, 6:00AM CDT
Allergan today launched #ActuallySheCanSM, an innovative campaign that inspires young millennial women to achieve their professional, personal, health, wellness and societal goals.
AGN: 314.95 (-0.40)
Tekmira suspends work on Ebola drug, will change name
AP - Mon Jul 20, 3:21PM CDT
NEW YORK (AP) — One of the companies that had been studying a potential treatment for the Ebola virus said Monday it will suspend its research on Ebola drugs and change its name.
AGN: 314.95 (-0.40), INO: 7.23 (-0.09), TKMR: 10.73 (+0.39), GSK: 42.00 (-0.30), TKM.TO: 22.97 (+0.52)
Are Any New FANGs Baring Their Teeth?
at The Street - Mon Jul 20, 10:27AM CDT
The fearsome foursome have been reborn.
AGN: 314.95 (-0.40), AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), BIIB: 385.05 (-6.69), GPRO: 63.95 (+2.27), AMZN: 482.18 (-6.09), VRX: 253.84 (+14.92), GILD: 117.66 (+0.22), FB: 95.44 (-1.60), GOOGL: 674.73 (-20.37), REGN: 556.61 (+0.08), CELG: 139.01 (+0.75), MS: 39.94 (-0.60)
Allergan to Highlight Data from Its Alzheimer's Disease Portfolio at the 2015 Alzheimer's Association International Conference (AAIC)
PR Newswire - Mon Jul 20, 8:00AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that five poster presentations will be given at the 2015 Alzheimer's Association International Conference in Washington DC, July 17 through July 23. Highlights include analyses on the use of memantine, extended-release memantine, and combination therapy with memantine and donepezil. The following data will be presented at this year's meeting:
AGN: 314.95 (-0.40)
Allergan May Be Recovering From Faded Rally
at The Street - Mon Jul 20, 7:00AM CDT
It's settling into an attractive pattern.
AGN: 314.95 (-0.40)
AstraZeneca Strikes Deal to Market Benralizumab in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 3:50PM CDT
AstraZeneca (AZN) inked a deal with Kyowa Hakko Kirin for the commercialization of benralizumab for asthma and chronic obstructive pulmonary disease in Japan.
AGN: 314.95 (-0.40), AZN: 66.55 (-0.67), AGIO: 118.42 (+1.04), AMAG: 71.31 (-1.23)
SAPHRIS® (asenapine) 2.5 mg Sublingual Tablets for the Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder in Pediatric Patients (ages 10-17) Now Available in Pharmacies throughout the U.S.
PR Newswire - Fri Jul 17, 7:00AM CDT
Allergan plc today announced that SAPHRIS® (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration (FDA) approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 - 17).
AGN: 314.95 (-0.40)
Which Top Biotechs Still In Play After Celgene Rally?
at Investor's Business Daily - Thu Jul 16, 5:45PM CDT
This week's list of leading stocks near buy points includes a healthy dose of medical names, from biotechs to managed care providers. The biotech revival began prior to Celgene's (CELG) 7% jump Wednesday on its $7.2 billion buy of Receptos (RCPT)....
MNK: 124.99 (-1.52), AGN: 314.95 (-0.40), VRX: 253.84 (+14.92), GILD: 117.66 (+0.22), UTHR: 175.10 (+0.50), RCPT: 228.27 (-0.13), MOH: 71.34 (-1.08), REGN: 556.61 (+0.08), CELG: 139.01 (+0.75)
Allergan Faces Patent Challenge for Eye Treatment Restasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 16, 1:35PM CDT
Allergan (AGN) is facing a patent challenge from Akorn for Restasis.
AGN: 314.95 (-0.40), EBIO: 2.91 (+0.01), MYL: 66.56 (-1.34), RDY: 61.74 (+0.26)
5 Big Stocks to Trade for Earnings Season Gains
at The Street - Thu Jul 16, 11:32AM CDT
Here's a technical look at how to trade some of the biggest stocks on Wall Street right now.
HRS: 82.09 (+0.48), BSX: 17.61 (-0.41), AGN: 314.95 (-0.40), HD: 114.59 (-0.31), HRL: 57.66 (-0.10)
The Antiepileptic Drug Topiramate Dominates First Line Prophylactic Treatment of Migraine, with Allergan's Botox Exhibiting Growth in Later Lines
PR Newswire - Thu Jul 16, 8:30AM CDT
Decision Resources Group finds that, through analysis of U.S. longitudinal patient-level claims data, the antiepileptic drug (AED) topiramate (Ortho-McNeil/Janssen-Cilag's Topamax; other brands; generics) captured the greatest patient share among prophylactic treatment-naive migraine patients across the first three lines of therapy. Furthermore, topiramate patient shares among migraine patients recently treated with prophylactic therapies remained relatively constant over the previous year of analysis. These findings highlight topiramate's position as a first-line standard of care for migraine prevention. Overall, AEDs were the preferred drug class for migraine prophylaxis, with nearly half of prophylactically naive patients initiating prophylactic therapy with an AED.
AGN: 314.95 (-0.40)
Top World Stocks In Bases Or Buy Range As Greece Votes
at Investor's Business Daily - Wed Jul 15, 4:50PM CDT
It's a good idea to scan through the charts of IBD's Top World Stocks. What you find right now is three of those stocks in bases and another two in buying range just above buy points. A resolution to the eurozone's crisis with Greece could quickly...
AGN: 314.95 (-0.40), MNK: 124.99 (-1.52), NTES: 150.58 (+0.41), SHPG: 261.24 (+1.78), ABBV: 70.52 (-0.04), FLTX: 49.63 (+0.95), ICLR: 67.90 (-0.22)
KYTHERA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of KYTHERA Biopharmaceuticals, Inc. (KYTH) Over the Proposed Sale of the Company to Allergan plc.
Business Wire - Thu Jul 23, 9:55AM CDT
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of KYTHERA Biopharmaceuticals, Inc. ("Kythera" or the "Company"
(NasdaqGS:KYTH) for potential breaches of fiduciary duties in connection with the sale of the Company to Allergan plc. for approximately $2.1 billion. The Company's stockholders will only receive approximately $75 per share for each share of Kythera common stock they own. AGN: 314.95 (-0.40), KYTH: 74.37 (-0.07)
Zacks Industry Outlook Highlights: AbbVie, Allergan, Pfizer, Juno and Johnson & Johnson - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 8:30AM CDT
Zacks Industry Outlook Highlights: AbbVie, Allergan, Pfizer, Juno and Johnson & Johnson
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), JUNO: 51.65 (-0.12), ABBV: 70.52 (-0.04)
Inotek Pharmaceuticals elects Dr Richard N. Spivey to board
M2 - Wed Jul 22, 4:58AM CDT
Biopharmaceutical company Inotek Pharmaceuticals (NasdaqGM:ITEK) revealed on Tuesday that it has appointed Richard N. Spivey, PharmD, PhD, to its board of directors.
AGN: 314.95 (-0.40), ITEK: 15.37 (+10.14)
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), ACHN: 8.97 (-0.12), PFE: 34.78 (-0.10), ABBV: 70.52 (-0.04), JUNO: 51.65 (-0.12), LLY: 86.76 (+0.38), SNY: 53.37 (+0.28)
Pharma Stock Outlook - July 2015 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Industry Outlook
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), ACHN: 8.97 (-0.12), PFE: 34.78 (-0.10), ABBV: 70.52 (-0.04), JUNO: 51.65 (-0.12), LLY: 86.76 (+0.38), SNY: 53.37 (+0.28)
Acne Vulgaris Pipeline Review 2015 - 40 Companies & 53 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtb2tv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advancell - Allergan, Inc. - AndroScience Corporation - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Cutanea Life Sciences - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - Dermira Inc. - ELORAC, Inc. - Ensoltek Co., Ltd. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Kasiak Research Pvt. Ltd. - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Nabriva Therapeutics AG - Novabiotics Ltd - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Provectus Biopharmaceuticals, Inc. - QLT Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mt...e_vulgaris
QLTI: 4.01 (unch), FOMX: 10.95 (-0.34), GSK: 42.00 (-0.30), PRTK: 25.84 (-0.57), AGN: 314.95 (-0.40), PVCT: 0.54 (+0.04), DERM: 24.19 (-0.72)
Technical Roundup on Drugs - Generic Equities -- Allergan, Akorn, Ironwood Pharma, Pacira Pharma, and Catalent
PR Newswire - Tue Jul 21, 8:15AM CDT
Equity Research Institute has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Catalent Inc. (NYSE: CTLT). Free research report on Allergan can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AGN On Monday, July 20, 2015, the NASDAQ Composite ended at 5,218.86, up 0.17%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 18,100.41, and the S&P 500 closed at 2,128.28, up 0.08%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
AGN: 314.95 (-0.40), IRWD: 11.41 (+0.07), AKRX: 46.01 (+0.32), CTLT: 30.40 (+0.47), PCRX: 62.10 (-0.03)
Inotek Pharmaceuticals Appoints Richard N. Spivey PharmD, Ph.D. to Board of Directors
Business Wire - Tue Jul 21, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for ocular diseases, today announced that Richard N. Spivey, PharmD, PhD, has been appointed to its Board of Directors.
AGN: 314.95 (-0.40), ITEK: 15.37 (+10.14)
Allergan Launches Bold Campaign For Millennial Women
PR Newswire - Tue Jul 21, 6:00AM CDT
Allergan today launched #ActuallySheCanSM, an innovative campaign that inspires young millennial women to achieve their professional, personal, health, wellness and societal goals.
AGN: 314.95 (-0.40)
Tekmira suspends work on Ebola drug, will change name
AP - Mon Jul 20, 3:21PM CDT
NEW YORK (AP) — One of the companies that had been studying a potential treatment for the Ebola virus said Monday it will suspend its research on Ebola drugs and change its name.
AGN: 314.95 (-0.40), INO: 7.23 (-0.09), TKMR: 10.73 (+0.39), GSK: 42.00 (-0.30), TKM.TO: 22.97 (+0.52)
Are Any New FANGs Baring Their Teeth?
at The Street - Mon Jul 20, 10:27AM CDT
The fearsome foursome have been reborn.
AGN: 314.95 (-0.40), AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), BIIB: 385.05 (-6.69), GPRO: 63.95 (+2.27), AMZN: 482.18 (-6.09), VRX: 253.84 (+14.92), GILD: 117.66 (+0.22), FB: 95.44 (-1.60), GOOGL: 674.73 (-20.37), REGN: 556.61 (+0.08), CELG: 139.01 (+0.75), MS: 39.94 (-0.60)
Allergan to Highlight Data from Its Alzheimer's Disease Portfolio at the 2015 Alzheimer's Association International Conference (AAIC)
PR Newswire - Mon Jul 20, 8:00AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that five poster presentations will be given at the 2015 Alzheimer's Association International Conference in Washington DC, July 17 through July 23. Highlights include analyses on the use of memantine, extended-release memantine, and combination therapy with memantine and donepezil. The following data will be presented at this year's meeting:
AGN: 314.95 (-0.40)
Allergan May Be Recovering From Faded Rally
at The Street - Mon Jul 20, 7:00AM CDT
It's settling into an attractive pattern.
AGN: 314.95 (-0.40)
AstraZeneca Strikes Deal to Market Benralizumab in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 3:50PM CDT
AstraZeneca (AZN) inked a deal with Kyowa Hakko Kirin for the commercialization of benralizumab for asthma and chronic obstructive pulmonary disease in Japan.
AGN: 314.95 (-0.40), AZN: 66.55 (-0.67), AGIO: 118.42 (+1.04), AMAG: 71.31 (-1.23)
SAPHRIS® (asenapine) 2.5 mg Sublingual Tablets for the Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder in Pediatric Patients (ages 10-17) Now Available in Pharmacies throughout the U.S.
PR Newswire - Fri Jul 17, 7:00AM CDT
Allergan plc today announced that SAPHRIS® (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration (FDA) approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 - 17).
AGN: 314.95 (-0.40)
Which Top Biotechs Still In Play After Celgene Rally?
at Investor's Business Daily - Thu Jul 16, 5:45PM CDT
This week's list of leading stocks near buy points includes a healthy dose of medical names, from biotechs to managed care providers. The biotech revival began prior to Celgene's (CELG) 7% jump Wednesday on its $7.2 billion buy of Receptos (RCPT)....
MNK: 124.99 (-1.52), AGN: 314.95 (-0.40), VRX: 253.84 (+14.92), GILD: 117.66 (+0.22), UTHR: 175.10 (+0.50), RCPT: 228.27 (-0.13), MOH: 71.34 (-1.08), REGN: 556.61 (+0.08), CELG: 139.01 (+0.75)
Allergan Faces Patent Challenge for Eye Treatment Restasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 16, 1:35PM CDT
Allergan (AGN) is facing a patent challenge from Akorn for Restasis.
AGN: 314.95 (-0.40), EBIO: 2.91 (+0.01), MYL: 66.56 (-1.34), RDY: 61.74 (+0.26)
5 Big Stocks to Trade for Earnings Season Gains
at The Street - Thu Jul 16, 11:32AM CDT
Here's a technical look at how to trade some of the biggest stocks on Wall Street right now.
HRS: 82.09 (+0.48), BSX: 17.61 (-0.41), AGN: 314.95 (-0.40), HD: 114.59 (-0.31), HRL: 57.66 (-0.10)
The Antiepileptic Drug Topiramate Dominates First Line Prophylactic Treatment of Migraine, with Allergan's Botox Exhibiting Growth in Later Lines
PR Newswire - Thu Jul 16, 8:30AM CDT
Decision Resources Group finds that, through analysis of U.S. longitudinal patient-level claims data, the antiepileptic drug (AED) topiramate (Ortho-McNeil/Janssen-Cilag's Topamax; other brands; generics) captured the greatest patient share among prophylactic treatment-naive migraine patients across the first three lines of therapy. Furthermore, topiramate patient shares among migraine patients recently treated with prophylactic therapies remained relatively constant over the previous year of analysis. These findings highlight topiramate's position as a first-line standard of care for migraine prevention. Overall, AEDs were the preferred drug class for migraine prophylaxis, with nearly half of prophylactically naive patients initiating prophylactic therapy with an AED.
AGN: 314.95 (-0.40)
Top World Stocks In Bases Or Buy Range As Greece Votes
at Investor's Business Daily - Wed Jul 15, 4:50PM CDT
It's a good idea to scan through the charts of IBD's Top World Stocks. What you find right now is three of those stocks in bases and another two in buying range just above buy points. A resolution to the eurozone's crisis with Greece could quickly...
AGN: 314.95 (-0.40), MNK: 124.99 (-1.52), NTES: 150.58 (+0.41), SHPG: 261.24 (+1.78), ABBV: 70.52 (-0.04), FLTX: 49.63 (+0.95), ICLR: 67.90 (-0.22)
